Full-year 2025 guidance was raised as sales are expected to grow high single digit and core operating income is expected to grow low double-digit. “We assume Tasigna, Promacta and Entresto US generic entry mid-2025 for forecasting purposes,” Novartis (NVS) stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis reports Q1 core EPS $2.28, consensus $2.11
- Novartis Reports Strong Q1 2025 Growth and Raises Full-Year Guidance
- Cautious Hold Rating for Novartis AG Amid Mixed Performance and Future Uncertainties
- Actinium Pharmaceuticals’ ATNM-400 shows efficacy in prostate cancer study
- Novartis price target lowered to $88 from $95 at HSBC